Brief: Bristol Myers Squibb Announces Positive Topline Results From The Interim Analysis Of Phase 3 ACTION-1 For RYZ101, Rayzebio’S Radiopharmaceutical Therapy, In Patients With GEP-NETS
12/10/2026 14:18
BRIEF-Bristol Myers Squibb Announces Positive Topline Results From The Interim Analysis Of Phase 3 ACTION-1 For RYZ101, Rayzebio’S Radiopharmaceutical Therapy, In Patients With GEP-NETS Oct 12 (Reuters) - Bristol-Myers Squibb Company BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE INTERIM ANALYSIS OF PHASE 3 ACTION-1 FOR RYZ101, RAYZEBIO’S RADIOPHARMACEUTICAL THERAPY, IN PATIENTS WITH GEP-NETS
BRISTOL-MYERS SQUIBB COMPANY - PHASE 3 ACTION-1 STUDY MEETS PRIMARY ENDPOINT WITH IMPROVED PROGRESSION-FREE SURVIVAL
BRISTOL-MYERS SQUIBB COMPANY - SAFETY RESULTS CONSISTENT WITH KNOWN RYZ101 SAFETY PROFILE
Source text: ID:nBwbw3n7Qa
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
BioNTech, Gilead to test drug combination in advanced breast cancer trial
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Bristol Myers Squibb To Showcase Next-Generation Cancer Modalities And Leadership Across Solid Tumors At Esmo 2026
US RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm